Latency transition of plasminogen activator inhibitor type 1 is evolutionarily conserved

Summary

Plasminogen activator inhibitor type 1 (PAI-1) is a central regulator of fibrinolysis and tissue remodelling. PAI-1 belongs to the serpin super-family and unlike other inhibitory serpins undergoes a spontaneous inactivation process under physiological conditions, termed latency transition. During latency transition the solvent exposed reactive centre loop is inserted into the central β–sheet A of the molecule, and is no longer accessible to reaction with the protease. More than three decades of research on mammalian PAI-1 has not been able to clarify the evolutionary advantage and physiological relevance of latency transition. In order to study the origin of PAI-1 latency transition, we produced PAI-1 from Spiny dogfish shark (Squalus acanthias) and African lungfish (Protopterus sp.), which represent central species in the evolution of vertebrates. Although human PAI-1 and the non-mammalian PAI-1 variants share only approximately 50 % sequence identity, our results showed that all tested PAI–1 variants undergo latency transition with a similar rate. Since the functional stability of PAI–1 can be greatly increased by substitution of few amino acid residues, we conclude that the ability to undergo latency transition must have been a specific selection criterion for the evolution of PAI-1. It appears that all PAI-1 molecules must harbour latency transition to fulfil their physiological function, stressing the importance to further pursue a complete understanding of this molecular phenomenon with possible implication to pharmacological intervention. Our results provide the next step in understanding how the complete role of this important protease inhibitor evolved along with the fibrinolytic system.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Conformational change - thermodynamic stability - urokinase - tissue type plasminogen activator - homology

• References

• 1 Andreasen PA. et al. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
• 2 Stein P, Chothia C. Serpin tertiary structure transformation. J Mol Biol 1991; 221: 615-621.
• 3 Kaslik G. et al. Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry 1997; 36: 5455-5464.
• 4 Im H, Yu MH. Role of Lys335 in the metastability and function of inhibitory serpins. Protein Sci 2000; 09: 934-941.
• 5 Huber R, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-8966.
• 6 Lee C. et al. Regulation of protein function by native metastability. Proc Natl Acad Sci USA 2000; 97: 7727-7731.
• 7 Jensen JK. et al. Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem 2011; 286: 29709-29717.
• 8 Huntington JA. et al. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-926.
• 9 Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751-4804.
• 10 Ricagno S. et al. Two latent and two hyperstable polymeric forms of human neu-roserpin. Biophys J 2010; 99: 3402-3411.
• 11 Lomas DA. et al. Preparation and characterization of latent alpha 1-antitrypsin. J Biol Chem 1995; 270: 5282-5288.
• 12 Whisstock J. et al. An atlas of serpin conformations. Trends Biochem Sci 1998; 23: 63-67.
• 13 Chang WS, Lomas DA. Latent alpha1-antichymotrypsin. A molecular explanation for the inactivation of alpha1-antichymotrypsin in chronic bronchitis and emphysema. J Biol Chem 1998; 273: 3695-3701.
• 14 Carrell RW. et al. Biological implications of a 3 A structure of dimeric antithrombin. Structure 1994; 02: 257-270.
• 15 Dupont DM. et al. Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 2009; 14: 1337-1361.
• 16 Mottonen J. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-273.
• 17 Tucker HM. et al. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol 1995; 02: 442-445.
• 18 Kruger P. et al. Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1. Protein Sci 2001; 10: 798-808.
• 19 Levin EG, Santell L. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood 1987; 70: 1090-1098.
• 20 Declerck PJ. et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-15461.
• 21 Lindahl TL. et al. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62: 748-751.
• 22 Sancho E. et al. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. Eur J Biochem 1994; 224: 125-134.
• 23 Hofmann KJ. et al. Purification and Characterization of Recombinant Rabbit Plasminogen-Activator Inhibitor-1 Expressed in Saccharomyces-Cerevisiae. Fibrinolysis 1992; 06: 263-272.
• 24 Bijnens AP. et al. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1. Thromb Haemost 1997; 77: 350-356.
• 25 Reilly CF. et al. Plasminogen-Activator Inhibitor-1 Suppresses Endogenous Fibrinolysis in a Canine Model of Pulmonary-Embolism. Circulation 1991; 84: 287-292.
• 26 Hekman CM, Loskutoff DJ. Endothelial-Cells Produce a Latent Inhibitor of Plasminogen Activators That Can Be Activated by Denaturants. J Biol Chem 1985; 260: 11581-11587.
• 27 Dewilde M. et al. Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. J Struct Biol 2010; 171: 95-101.
• 28 Bager R. et al. Protein conformational change delayed by steric hindrance from an N-linked glycan. J Mol Biol 2013; 425: 2867-2877.
• 29 Jensen JK. et al. The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand. FEBS Lett 2002; 521: 91-94.
• 30 Hansen M. et al. Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms. Eur J Biochem 2001; 268: 6274-6283.
• 31 Chana-Muñoz A. et al. Multi-tissue RNA-seq and transcriptome characterisation of the spiny dogfish shark (Squalus acanthias) provides a molecular tool for biological research and reveals new genes involved in osmoregulation. PLoS One. 2017
• 32 Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 09: 357-359.
• 33 Altschul SF. et al. Basic local alignment search tool. J Mol Biol 1990; 215: 403-410.
• 34 Rheinwald JG. et al. Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J Cell Biol 1987; 104: 263-275.
• 35 Tom R. et al. Culture of HEK293-EBNA1 Cells for Production of Recombinant Proteins. CSH Protoc. 2008 2008. pdb prot4976.
• 36 Fersht A. Structure and Mechanism in Protein Science. 1999. New York: W. H. Freeman and Company;
• 37 Schar CR. et al. Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem 2008; 283: 28487-28496.
• 38 Lawrence DA. et al. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem 1994; 269: 27657-27662.
• 39 Robertson JD. Osmotic Constituents of the Blood-Plasma and Parietal Muscle of Scyliorhinus-Canicula (L). Comp Biochem Physiol 1989; 93: 799-805.
• 40 Lawrence DA. et al. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem 1997; 272: 7676-7680.
• 41 Wun TC. et al. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin. J Biol Chem 1989; 264: 7862-7868.
• 42 Bruce D. et al. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp). J Clin Invest 1994; 94: 2265-2274.
• 43 Gooptu B. et al. Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA 2000; 97: 67-72.
• 44 Declerck PJ, Gils A. Three Decades of Research on Plasminogen Activator In-hibitor-1: A Multifaceted Serpin. Semin Thromb Hemost 2013; 39: 356-364.
• 45 Nykjaer A. et al. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994; 269: 25668-25676.
• 46 Mayer EJ. et al. The Pharmacokinetics of Plasminogen-Activator Inhibitor-1 in the Rabbit. Blood 1990; 76: 1514-1520.
• 47 Eren M. et al. Role of Plasminogen Activator Inhibitor-1 in Senescence and Aging. Semin Thromb Hemost 2014; 40: 645-651.
• 48 Zhou AW. et al. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 2003; 10: 541-544.
• 49 Berkenpas MB. et al. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995; 14: 2969-2977.
• 50 Vleugels N. et al. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1. Thromb Haemost 2000; 84: 871-875.
• 51 Gorlatova NV. et al. Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function. J Biol Chem 2003; 278: 16329-16335.
• 52 Yi JY, Im H. Structural factors affecting the choice between latency transition and polymerization in inhibitory serpins. Protein Sci 2007; 16: 833-841.
• 53 Blouse GE. et al. Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1. Biochemistry 2003; 42: 12260-12272.
• 54 Dupont DM. et al. Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem 2006; 281: 36071-36081.
• 55 Hickman CP. et al. Integrated Principles of Zoology. 2001. Eleventh Edition. New York: McGraw-Hill;